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A B S T R A C T
Background: Despite its efficacy, medication-assisted treatment (MAT) is rarely available in the criminal justice
system in the United States, including in problem-solving courts or diversionary settings. Previous studies have
demonstrated criminal justice administrators' hostility towards MAT, especially in prisons and jails. Yet, few
studies have examined attitudes among court personnel or compared beliefs among different types of personnel.
Also, few studies have explored the relationship between MAT education/training and attitudes. Finally, few
studies have directly compared attitudes towards methadone, oral buprenorphine, and extended-release nal-
trexone in the criminal justice system.
Methods: We modified a survey by Matusow et al. (2013) to explore justice professionals' MAT attitudes, in-
cluding associations with demographic variables, court role, and previous MAT education/training. After pi-
loting the survey, we distributed it to a convenience sample of justice professionals registered for an educational
summit held in Indiana in 2018. Data was analyzed using descriptive and inferential statistical methods.
Results: 231 Indiana court employees who had registered for a state MAT educational summit completed the
survey prior to the summit, including judges, probation officers, law enforcement personnel, attorneys, proba-
tion officers, program directors, counselors, and case managers. Overall, participants had significantly more
positive attitudes towards extended-release naltrexone than towards other medications (p value<0.01). Court
employee average attitudes towards methadone were significantly more negative than average attitudes towards
oral buprenorphine; and average attitudes towards oral buprenorphine were significantly more negative than
average attitudes towards extended-release naltrexone (p value<0.01). Employment as a prosecutor or law
enforcement officer was associated with more negative attitudes towards oral buprenorphine and methadone (p
value< 0.05). Exposure to previous MAT training was associated with more positive attitudes for all medica-
tions (p value< 0.05). Compared to participants with graduate degrees, participants with less education had
significantly more negative attitudes towards extended-release naltrexone (p < 0.05). Gender, age, rurality, and
personal/family recovery history were not associated with differences in attitudes.
Conclusion: As expected, court employees' attitudes significantly differ by medication, with average attitudes
towards agonist medications being more negative than attitudes towards extended-release naltrexone. Despite a
larger evidence base for the efficacy of methadone and oral buprenorphine, justice personnel may have more
positive attitudes towards extended-release naltrexone due to targeted marketing by the pharmaceutical man-
ufacturer, fears about diversion or misuse of agonist medications, and historic criminal justice hostility towards
agonist medications. Importantly, previous education/training regarding MAT is associated with more positive
attitudes, suggesting that more awareness-raising or capacity building educational interventions are needed,
especially for prosecutors and law enforcement personnel.
1. Introduction
Approximately two million Americans have an opioid use disorder
(OUD) (National Institutes of Health, 2016). Individuals with OUD are
at significant risk of opioid overdose, a particularly pressing problem in
the U.S. where opioid-related death rates have quadrupled nationally
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since 2000 (Dowell et al., 2017) and contributed to decreased average
life expectancy (Dowell et al., 2017). Individuals with OUD are also
overrepresented in the U.S. criminal justice system, with an estimated
24% to 36% of Americans with OUD cycling in or out of jail annually
(Results from the 2012 National Survey on drug use and health: Summary of
National Findings, 2013; Rich et al., 2005).
Evidence-based treatment for OUD includes three medications ap-
proved by the Food and Drug Administration: methadone, buprenor-
phine, and naltrexone (collectively referred to as medication-assisted
treatment, or “MAT”).1 Although treatment should be individualized
and include behavioral treatment (e.g. mental health therapy), MAT is
more effective than behavioral treatment alone (Potter et al., 2013),
and MAT is associated with significant decreases in opioid overdose
rates, opioid misuse rates, criminal activity, and HIV/AIDS incidence
(Jarvis et al., 2018; Kelty & Hulse, 2017; Larochelle et al., 2018;
Mattick, Breen, Kimber, & Davoli, 2014; Sharma et al., 2016; Sordo
et al., 2017). At moderate doses, methadone, a full opioid agonist, and
buprenorphine, a partial opioid agonist, are considered equivalently
effective at preventing opioid misuse and overdose, although some
studies have found longer treatment retention rates with methadone
(Mattick et al., 2014; Nielsen, Larance, & Lintzeris, 2017). Methadone
and buprenorphine have a stronger evidence base than does naltrexone,
but extended-release naltrexone may be as effective as oral buprenor-
phine in preventing opioid misuse and overdose for some populations
(Lee et al., 2018; Morgan, Schackman, Leff, Linas, & Walley, 2018;
Tanum et al., 2017). Unlike methadone, which may only be accessed
via highly-regulated, stand-alone opioid treatment programs (“metha-
done clinics”), buprenorphine and naltrexone formulations may be
accessed in office-based settings. However, to prescribe buprenorphine
healthcare practitioners must obtain a waiver from the Substance Abuse
and Mental Health Services Administration (SAMHSA) (Medications for
Opioid Use Disorder TIP 63 Treatment Improvement Protocol For
Healthcare and Addiction Professionals, Policymakers, Patients, and
Families, 2018). Unlike buprenorphine or methadone treatment, nal-
trexone treatment requires complete detoxification prior to induction,
which can be a significant hurdle for many people with OUD (Lee et al.,
2017), especially given the undersupply and cost of inpatient detox-
ification services in many areas (Andraka-Christou & Capone, 2018).
Additionally, the injectable form of naltrexone is significantly more
expensive than methadone and oral buprenorphine, both of which are
available in generic formulations (Jackson, Mandell, Johnson,
Chatterjee, & Vanness, 2015).
Despite MAT's efficacy, it is significantly underused in U.S. drug
courts, jails, and prisons (Hedrich et al., 2012; Ludwig & Peters, 2014;
Matusow et al., 2013; Nordstrom & Marlowe, 2016; Nunn et al., 2009).
According to one study, among criminal justice system participants
referred to OUD treatment, only 5% received a referral for either bu-
prenorphine or methadone treatment (Krawczyk, Picher, Feder,
Student, & Saloner, 2017). Furthermore, in that study participants who
were referred to OUD treatment by problem-solving courts or other
diversionary programs (e.g. programs where charges are dropped fol-
lowing successful treatment) were less likely to receive a referral for
buprenorphine or methadone than were those who received a referral
for OUD treatment from probation, parole, or prison (Krawczyk et al.,
2017). Reasons for lack of MAT referral in the criminal justice system
include negative attitudes towards MAT, such as beliefs that it is in-
effective for OUD, has a high potential for misuse or diversion, is dif-
ficult to administer, and is costly (Bruce & Schleifer, 2008; Friedmann
et al., 2012; Gordon, Vocci, Fitzgerald, O'Grady, & O'Brien, 2017;
Matusow et al., 2013; Sharma et al., 2016).
To date, few studies have examined the attitudes towards MAT or
referral practices of criminal justice personnel working in court settings
(i.e. judges and their staff), with most studies focusing on the attitudes
and practices of prison and jail administrators (Chandler, Fletcher, &
Volkow, 2009; Lee et al., 2016; Ludwig & Peters, 2014; Matusow et al.,
2013). Yet court personnel influence whether or not an individual who
lives in the community but participates in problem-solving courts, pre-
trial diversion, or probation may access MAT (Andraka-Christou, 2017;
Matusow et al., 2013).
A previous study found that court personnel's attitudes towards
MAT strongly predict whether participants may access MAT (Matusow
et al., 2013). Specifically, court personnel's attitudes about the fol-
lowing are strong predictors of MAT availability in adult drug courts:
MAT efficacy in preventing relapse, MAT effectiveness relative to psy-
chosocial treatments, and maintenance MAT (use over an extended
period) (Matusow et al., 2013). Therefore, researchers and policy ma-
kers need more information about court personnel's attitudes towards
MAT and potential influences on these attitudes. Additionally, little is
known regarding whether and how previous education and training
about MAT influences attitudes towards MAT. Such information could
inform policy initiatives to expand MAT access.
The largest study of court personnel's attitudes towards MAT was
published by Matusow et al. in 2013, using data obtained in 2010
(Matusow et al., 2013). In a national sample of over 100 adult drug
court personnel, the study found widespread uncertainty and negative
attitudes towards methadone and buprenorphine, with 10% of court
staff viewing MAT as a “reward” for criminal behavior (Matusow et al.,
2013). The study also found that up to 50% of adult drug courts na-
tionally prohibited program enrollee use of methadone or buprenor-
phine for reasons ranging from concerns about efficacy and diversion to
cost and lack of providers (Matusow et al., 2013). In a 2017 report of
drug court practices in three states, the organization Physicians for
Human Rights stated that non-medical personnel routinely prohibited
MAT and made medical decisions best left to medical personnel (Neither
Justice Nor Treatment Drug Courts in the United States, 2017). The Na-
tional Association of Drug Court Professionals (NADCP), a nonprofit
organization that issues non-binding best practice standards for drug
courts, stated that individuals who are legally prescribed “addiction
medication” should be eligible to participate in drug court programs
(Adult Drug Court Best Practice Standards, 2018). Moreover, the orga-
nization passed a unanimous resolution directing drug courts to “learn
the facts about MAT” (Adult Drug Court Best Practice Standards, 2018).
Additionally, under the Obama Administration, SAMHSA passed a re-
solution prohibiting federal funding for drug courts that fail to permit
MAT (Davies, 2015). However, a previous qualitative study of Indiana
drug court judges reported that judges felt the policy had limited effect,
because they primarily received state and local funding for drug courts
(Andraka-Christou, 2017).
The Matusow et al. study focused exclusively on adult drug court
personnel and predated publication of the NADCP standards described
above (Adult Drug Court Best Practice Standards, 2018; Matusow et al.,
2013). The study did not examine attitudes of personnel in other types
of problem-solving courts (e.g., veterans courts and family courts), nor
did the study examine attitudes of personnel in non-problem-solving
courts (e.g. felony courts and misdemeanor courts.) Problem-solving
courts other than adult drug courts have participants with OUD, and
these courts can require and monitor treatment for OUD. Data is not
available regarding the percentage of other problem-solving courts'
participants who have OUD; however, state court system directors, in-
cluding chief justices, have urged all problem-solving courts to expand
OUD treatment interventions in response to the ongoing opioid crisis
(Pariente, n.d.). Additionally, many non-problem-solving courts have
pretrial diversion programs in which people charged with substance use
disorder-related crimes may have their charges dropped upon suc-
cessful completion of substance use disorder treatment (Pretrial
1 We use the term “medication-assisted treatment” throughout the manuscript
to refer to methadone, buprenorphine, and naltrexone treatment, both with or
without psychosocial treatment methods. However, some scholars use MAT to
refer to the combination of these medications with psychosocial treatment
methods.
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Diversion, n.d.). Information about personnel's attitudes in other types
of courts would allow researchers and policymakers to design educa-
tional initiatives for personnel outside of adult drug courts. Designing
education for a broader audience is important given that drug court
staff may differ in knowledge and attitudes from staff in other courts.
In addition, the Matusow et al. study did not examine attitudes re-
lated to extended-release naltrexone (Matusow et al., 2013), which is an
antagonist, meaning it blocks opioid receptors in the brain. In contrast,
oral buprenorphine and methadone are agonists, meaning they activate
opioid receptors in the brain. Therefore, court personnel concerns re-
lated to diversion and misuse may be lower for extended-release nal-
trexone. On the other hand, relative to agonist treatments (i.e. metha-
done and buprenorphine), fewer studies exist assessing extended-
release naltrexone's efficacy for OUD; therefore, it is possible that court
personnel believe extended-release naltrexone is less efficacious than
agonist treatments. Finally, the Matusow et al. study did not examine
the relationship between previous MAT education/training and atti-
tudes towards MAT (Matusow et al., 2013).
Considering the growing opioid overdose problem, a more recent
study of MAT attitudes in court settings is critically needed, including
settings beyond adult drug courts. To help address this gap, we mod-
ified the survey of Matusow et al. (Matusow et al., 2013) and im-
plemented it in Indiana in 2018 with the goal of ascertaining court
personnel's attitudes towards methadone, oral buprenorphine, and ex-
tended-release naltrexone. Additionally, our study aimed to ascertain
any relationship between previous formal MAT education or training in
court personnel's professional capacity and attitudes towards MAT.
Education could help dispel some of common myths about MAT, such
as that it is “just another drug,” thereby impacting attitudes towards
MAT.
Finally, we aimed to identify associations between demographic
variables and attitudes towards MAT. For example, we probed asso-
ciations between court personnel's gender and attitudes, because a
systematic review of gender differences in attitudes towards mental
health treatment found that women are more likely to endorse psy-
chosocial conceptions of mental illness and that women tend to view
treatment outcomes more favorably (Holzinger, Floris, Schomerus,
Carta, & Angermeyer, 2012). We also aimed to identify any associations
between rurality and attitudes, because a previous study found that
fewer SAMHSA-waivered physicians exist in rural areas(Rosenblatt,
Andrilla, Catlin, & Larson, 2015); and the presence of a SAMHSA-
waivered physician may mediate criminal justice personnel's attitudes
towards buprenorphine. Additionally, Matusow et al. previously found
that rurality was associated with some negative attitudes towards bu-
prenorphine and methadone (Matusow et al., 2013).
We recruited court personnel who were registered for a statewide
MAT education summit for completion of our survey prior to the be-
ginning of the summit. While these results may not be generalizable
outside of Indiana and it is unclear how representative the attitudes are
of court personnel throughout the state, we believe the results can in-
form researchers' and Indiana state policy makers' proposed policies for
expanding MAT access in court settings, including informational in-
itiatives about MAT.
2. Methods & materials
We modified Matusow et al.'s instrument (Matusow et al., 2013),
creating a brief, anonymous survey to explore court professionals' at-
titudes towards MAT. See the Appendix. The survey was fielded in In-
diana in July 2018, and collected information about court professionals'
demographics, attitudes towards MAT, and previous MAT education.
Prior to launching the survey, we pilot-tested it with three problem-
solving court judges in Indiana using a cognitive interviewing process
(Willis, 1999, 2005) and modified questions based on their feedback.
2.1. Participant recruitment
We recruited a convenience sample from registered participants of
the Indiana Statewide Opioid Summit, a special event in July 2018
sponsored by the Indiana Supreme Court, Indiana Family and Social
Services Agency, the Association of Indiana Counties, and Indiana
University. The summit topic was “A Medication-Assisted Treatment
and Addictions Primer for Justice Professionals.” We provided a link to
the online survey to summit organizers, who then emailed the link to
the 947 individuals registered for the summit. The summit's primary
audience were employees in the state court and criminal justice sys-
tems, including judges, probation officers, law enforcement officers,
health care practitioners, defense attorneys, prosecutors, and others.
Participants were not provided an incentive for participation in the
survey.
2.2. Data collected
2.2.1. Role in the court
We collected information from respondents about their role in the
court. Respondents could choose from the following options: case
manager, defense attorney, Department of Child Services attorney,
judge, law enforcement officer, mental health/substance use disorder
counselor (bachelor's degree), mental health/substance use disorder
counselor (master's degree or higher), physician, probation officer,
prosecutor, problem-solving court director, or other. Respondents could
also choose not to disclose their role.
2.2.2. Demographics
We collected demographic information from respondents, including
age, gender, educational attainment, and whether they were employed
in an urban or rural county. While attendees at the summit came from
court programs in all 92 Indiana counties, due to justice professionals'
concerns about anonymity, we did not attempt to link respondents'
responses to specific geographic areas. We also asked whether the re-
spondent or a close family member was in recovery for a substance use
disorder. Respondents could also choose not to disclose demographic
data.
2.2.3. MAT Attitudes
Our survey included eight statements about each medication (me-
thadone, oral buprenorphine, and extended-release naltrexone), which
respondents were asked to rate on a five-point Likert scale that ranged
from “strongly disagree” (1) to “strongly agree” (5) (see Tables 2 and 3
for statements about MAT attitudes reported in this article). These
questions about MAT attitudes were modified from Matusow et al.'s,
2013 survey (Matusow et al., 2013).
We did not include statements about extended-release buprenor-
phine formulations (injectable or implantable) given their very recent
FDA approvals. We also did not include statements about oral nal-
trexone, given its limited efficacy due to low adherence rates (Kjome &
Moeller, 2011; Sullivan et al., 2018). Respondents could choose not to
answer questions about MAT. Even though the Matusow et al. study
used a three-point scale, we used a five-point scale, believing it would
better allow us to discriminate between measures.
2.2.4. Previous Education about MAT
We asked respondents, “Have you previously received any formal
education or training about medication-assisted treatment in your ca-
pacity as a court employee?” Respondents could also choose not to
disclose whether they had previously received education or training
about MAT.
The survey was implemented in Qualtrics software. The study was
approved by the Indiana University Human Subjects Institutional
Review Board.
B. Andraka-Christou, et al. Journal of Substance Abuse Treatment 104 (2019) 72–82
74
2.3. Analysis
Descriptive statistics were explored to capture the demographic
information for survey respondents. Differences between respondents'
attitudes towards MAT were explored using bivariate statistics.
Analyses of variance (ANOVA) were used to analyze average differences
in attitudes across the three MAT treatment categories. T-Tests were
used to compare the difference between average attitudes between
certain key demographic groups, including gender, rurality, and whe-
ther the court personnel had previously received formal MAT education
or training. Multivariate linear regression was used to analyze the as-
sociations between respondents' demographic characteristics and their
attitudes towards MAT treatments. All statistical analyses were con-
ducted using SAS Enterprise Guide 9.4.
Due to a limited number of respondents in some categories of justice
professionals, for purposes of analysis we combined the following
personnel: judges and problem-solving court program director (due to
their leadership roles in court programs); law enforcement officers and
prosecutors (due their law enforcement background); and mental
health/substance use counselor with a bachelor's degree, mental
health/substance use counselor with a master's degree or higher, case
managers, and physicians (due to their health care focus). Probation
officers and corrections officials were combined due to their back-
ground in corrections. The “other” category included defense attorneys,
Department of Children Services attorneys, and respondents who either
identified as “other” or did not state their professions. Other groupings
of court personnel were explored, and findings were robust to these
sensitivity analyses.
For purposes of data analysis and presentation, we reverse-coded
some of the Likert scale items, a process commonly followed in survey data
analysis (Józsa & Morgan, 2017), so that a high value indicates the same
type of response (e.g. a positive attitude) to every item. Specifically, for any
statements that presented a substance negatively (e.g. “methadone does
not reduce or block the effects of heroin; 1=strong disagreement and
5=strong agreement), we reverse-coded those statements and asso-
ciated Likert scale items to present the substance positively (e.g. me-
thadone reduces or blocks the effects of heroin; 1=strong agreement
and 5=strong disagreement). In total, we reverse-coded three state-
ments: “substance rewards criminals for being drug users,” “substance
prolongs addiction,” and “substance interferes with one's ability to
drive a car.”
3. Results
We collected data from 235 justice personnel in Indiana who had
registered for the MAT education summit. For purposes of analysis, we
excluded data from four respondents who completed the survey after
the summit had begun, in case summit participation influenced atti-
tudes. Therefore, our final sample included data from 231 respondents
(a 24% response rate), all of whom provided responses prior to the
beginning of the summit.
3.1. Respondent characteristics
3.1.1. Demographic data
Approximately half of the respondents disclosed they were female
(46%; n=104) and more than one-third disclosed they were male
(39%; n=89); the remainder did not disclose their gender. More than
half indicated they worked in a rural county (58%; n=134), while a
quarter worked in an urban county (25%; n=56), with the remainder
not disclosing. One quarter stated that they or a close family member
were in recovery from a substance use disorder (21%; n=48); almost
three quarters stated that neither they nor a close family member were
in recovery (62%; n=143), with a few choosing not to disclose. About
half were younger than 50 years old (48%; n=110), more than a third
were older than 50 years old (36%; n=84), with the remainder not
disclosing their age. More than half of respondents had a graduate
degree (50%; n=116); a quarter had a bachelor's degree (25%;
n=58); and only 8% (n=20) had neither a bachelor's nor a graduate
degree; the remainder did not disclose their education completion. See
Table 1.
3.1.2. Previous formal MAT education or training in capacity as court
employee
Slightly more respondents had received formal MAT education or
training in their capacity as a court employee prior to the summit (45%;
n=103) as compared to those who had not (40%; n=93), with the
remainder choosing not to disclose.
3.1.3. Professional role in the court
The most common professional roles in the court were “other”
(23%; n=55), probation officers (19%; n=44), and judges (18%;
n=43). About one-tenth (10%; n=25) were healthcare professionals,
such as a mental health SUD/counselor, physician, or case manager.
Less common were law enforcement officers (8%; n=18), prosecutors
(7%; n=16), defense attorneys (5%, n=11), problem-solving court
directors (3%; n=7), and Department of Child Services attorneys
(n=3; 1%). A few (4%; n=9) chose not to disclose their role in the
court.
3.2. Attitudes towards MAT
Of the 231 respondents who submitted survey responses, 192 re-
spondents answered all questions about MAT attitudes (see Tables 2
Table 1
Descriptive statistics for court personnel.
Characteristics of respondents N %
Gender: female 104 46%
Gender: male 89 39%
Prefer not to disclose 38 17%
Court: rural Area 133 58%
Court: urban Area 56 25%
Prefer not to disclose 42 19%
Age: 18–29 6 3%
Age: 30–49 104 45%
Age: 50–64 75 32%
Age: 65+ 9 4%
Prefer not to disclose 37 16%
Case manager 6 3%
Defense attorney 11 5%
Department of Child Services attorney 3 1%
Judge 43 18%
Law enforcement officer 18 8%
Mental health/SUD counselor - bachelor's Degree 2 1%
Mental health/SUD counselor - master's Degree Higher 15 6%
Other 55 23%
Physician (MD) 2 1%
Probation officer 44 19%
Problem-solving court director/coordinator 7 3%
Prosecutor 16 7%
Prefer not to disclose 9 4%
Associate degree 3 1%
Bachelor's degree 58 25%
Graduate or professional degree 116 50%
High school graduate 1 0%
Some college 6 3%
Some graduate work 8 3%
Trade/technical/vocational training 2 1%
Prefer not to disclose 37 16%
No: You or a close family member are in recovery 143 62%
Yes: You or a close family member are in recovery 48 21%
Prefer not to disclose 40 17%
No previous formal MAT education/training 93 40%
Previous formal MAT education/training 103 45%
Prefer not to disclose 35 15%
MAT=medication-assisted treatment; SUD= substance use disorder.
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and 3 for detailed responses).
Across all questions regarding MAT attitudes, respondents had sig-
nificantly more negative attitude towards methadone than oral bupre-
norphine, and significantly more negative attitudes towards oral bu-
prenorphine than extended-release naltrexone. See Tables 2 and 3.
On average, court personnel did not choose a 4 or 5 on the Likert
scale (indicating “somewhat agree” or “strongly agree”) with positive
statements about any of the medications. Average agreement with po-
sitive statements about the substances on a scale of 1–5 were as follows:
3.00 for methadone; 3.22 for oral buprenorphine, and 3.82 for ex-
tended-release naltrexone.
Sixty-one percent agreed or strongly agreed with the statement
“extended-release naltrexone does not reward criminals for being drug
users.” In contrast, approximately half (54%) agreed or strongly agreed
with the statement “methadone does not reward criminals for being
drug users,” and half (51%) agreed or strongly agreed with the state-
ment “oral buprenorphine does not reward criminals for being drug
users.”
Forty-eight percent agreed or strongly agreed with the statement
“extended-release naltrexone does not prolong addiction.” In contrast,
only (27%) agreed or strongly agreed with the statement “buprenor-
phine does not prolong addiction,” and a quarter (25%) agreed or
strongly agreed with the statement “methadone does not prolong ad-
diction.” See Table 3 for level of agreement with other statements about
the medications.
More than half of our sample believed that methadone and bupre-
norphine prevent relapse (51% for methadone; 59% for buprenor-
phine;). Almost two-thirds believed that extended-release naltrexone
prevents relapse (71%) and should be used to maintain clients with
OUD (62%). More than a third of our sample believed that clients
should be maintained on methadone (36%), and more than half (53%)
believed that clients should be maintained on buprenorphine.
About a third of our sample believed that methadone is more ef-
fective than non-pharmacological approaches to treatment and that
buprenorphine is more effective than non-pharmacological approaches
(35% and 41%, respectively). Over half (59%) of our sample believed
that extended-release naltrexone is more effective than non-pharma-
cological approaches.
3.3. Bivariate relationships between respondents' attitudes and other
variables
We compared the average attitudes towards MAT between key de-
mographic groupings (see Table 4). We found that average attitudes did
Table 2
Average attitudes about medication-assisted treatments.
Questions about attitudes Methadone Buprenorphine Vivitrol Sig. ANOVA
SUBSTANCE reduces relapse 3.2 3.46 3.97 p < 0.001
SUBSTANCE reduces crime and re-incarceration 2.85 3.03 3.67 p < 0.001
SUBSTANCE does not reward criminals for being drug users 3.56 3.54 3.94 p < 0.001
SUBSTANCE does not prolong addiction 2.51 2.70 3.58 p < 0.001
SUBSTANCE should be used to maintain clients who have OUD 3 3.40 3.88 p < 0.001
SUBSTANCE is more effective than non-pharmacological approaches to retaining clients in treatment 3.08 3.25 3.80 p < 0.001
SUBSTANCE does not interfere with one's ability to drive a car 2.72 2.99 3.71 p < 0.001
SUBSTANCE reduces or blocks the effect of heroin 3.12 3.41 3.98 p < 0.001
Avg =3.00 Avg=3.22 Avg=3.82
OUD=opioid use disorder.
Table 3
Attitudes about medication-assisted treatments.
%SD %D %Neutral/Unsure %A %SA
Methadone
Methadone reduces relapse 14 16 18 38 13
Methadone reduces crime and re-incarceration 20 20 26 24 10
Methadone does not reward criminals for being drug users 5 17 23 24 30
Methadone does not prolong addiction 26 33 16 14 11
Methadone should be used to maintain clients who have OUD 12 22 30 25 11
Methadone is more effective than non-pharmacological approaches to retaining clients in treatment 8 19 38 26 9
Methadone does not interfere with one's ability to drive a car 15 23 44 12 6
Methadone reduces or blocks the effect of heroin 14 13 34 24 15
Oral Buprenorphine
Oral buprenorphine reduces relapse 8 15 18 43 16
Oral buprenorphine reduces crime and re-incarceration 16 18 24 32 11
Oral buprenorphine does not reward criminals for being drug users 4 14 31 25 26
Oral buprenorphine does not prolong addiction 17 32 24 18 9
Oral buprenorphine should be used to maintain clients who have OUD 7 12 28 40 13
Oral buprenorphine is more effective than non-pharmacological approaches to retaining clients in treatment 6 16 38 30 11
Oral buprenorphine does not interfere with one's ability to drive a car 8 21 46 15 11
Oral buprenorphine reduces or blocks the effect of heroin 6 12 35 29 18
Extended-Release Naltrexone
2 5 23 37 34
Extended-release naltrexone reduces crime and re-incarceration 5 4 31 38 22
Extended-release naltrexone does not reward criminals for being drug users 2 5 32 19 42
Extended-release naltrexone does not prolong addiction 4 9 40 21 27
Extended-release naltrexone should be used to maintain clients who have OUD 2 4 32 30 32
Extended-release naltrexone is more effective than non-pharmacological approaches to retaining clients in treatment 2 4 36 32 27
Extended-release naltrexone does not interfere with one's ability to drive a car 1 3 52 12 32
Extended-release naltrexone reduces or blocks the effect of heroin 1 3 34 22 41
SD= Strongly Disagree, D=Somewhat Disagree, A= Somewhat Agree, SA= Strongly Agree; OUD=opioid use disorder.
B. Andraka-Christou, et al. Journal of Substance Abuse Treatment 104 (2019) 72–82
76
not differ significantly by gender for any MAT treatment (P > 0.05).
When we explored the bivariate relationship between average attitudes
by rurality, we found that respondents that worked in courts in rural
counties had significantly more negative attitudes towards MAT than
those working in urban areas (p < 0.05). Average attitudes were also
significantly different based on whether respondents had received
formal MAT education or training prior to the summit in their capacity
as a court employee. Average attitudes for methadone were 2.84 on a
five-point Likert scale for those without formal MAT education or
training compared with 3.15 for those with formal MAT education or
training (p < 0.05). When average attitudes towards oral buprenor-
phine were compared across these two categories, we found that atti-
tudes were significantly different, with 3.05 for those without previous
formal MAT education or training and 3.38 for those with previous
formal MAT education or training (p < 0.05). Average attitudes were
also different for extended-release naltrexone across groups, with 3.49
for those without previous formal MAT education or training and 4.1
Table 4
Multivariate regression analyses.
Covariates Average Attitudes About Methadone Average Attitudes about Oral
Buprenorphine
Average Attitudes about Extended-Release
Naltrexone
Estimate Sig. Estimate Sig. Estimate Sig.
Female −0.06711 0.565 −0.01777 0.8745 0.12436 0.1763
Male ref ref ref
18–29 Years ref ref ref
30–49 Years −0.21601 0.4784 −0.24603 0.4031 −0.04405 0.8541
50–64 Years −0.25569 0.41 −0.35565 0.2357 −0.08507 0.7273
65+ Years 0.24628 0.5406 −0.02794 0.9426 −0.079 0.8029
Less than a college degree −0.45953 0.0822 −0.2469 0.3319 −0.41565 0.046⁎
Bachelor's degree −0.23724 0.0804 −0.18667 0.1535 −0.21352 0.0458⁎
Graduate or professional degree ref ref ref
You or close family member are in recovery 0.13428 0.2978 0.07956 0.5224 0.14787 0.1457
Neither you nor a close family member are in
recovery
ref ref ref
Prefer not to disclose if you or close family
member are in recovery
−0.61522 0.1465 −0.215 0.5981 −0.17774 0.5929
Urban ref ref ref
Rural −0.14224 0.2338 −0.18324 0.1127 −0.16276 0.0841⁎
No previous formal MAT education/training in
capacity as court employee
ref ref ref
Previous formal MAT education/training in
capacity as court employee
0.22763 0.0407⁎ 0.23416 0.0293⁎ 0.45996 <0.0001⁎
Corrections 0.28063 0.1652 0.54809 0.0054⁎ −0.01369 0.9313
Judge −0.24873 0.1619 −0.06335 0.7114 −0.10608 0.4474
Law Enforcement −0.40444 0.0418⁎ −0.52925 0.0061⁎ −0.04109 0.7915
Other 0.19096 0.2447 0.15189 0.3375 −0.14178 0.2722
Healthcare ref ref ref
MAT=medication-assisted treatment.
⁎ Items in bold were statistically significant at p < 0.05.
Fig. 1. Average Attitudes by Gender.
Not significantly different from each other p < 0.05.
Fig. 2. Average Attitudes by Rurality.
*significantly different from each other p < 0.05.
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for those with formal MAT education or training (p < 0.05). See
Figures 1 and 2.
3.4. Multivariate relationships between respondents' attitudes and other
variables
Below we report relationships between respondents' attitudes to-
wards MAT and other variables, including gender, age, educational
attainment, whether they had a close family in recovery, rurality,
previous formal MAT education or training, and role in the court. See
Table 4.
After controlling for the above characteristics, gender was not sig-
nificantly associated with respondents' attitudes towards any of the
medications. Also, after controlling for other variables, rural or urban
locations were not significantly associated with attitudes towards any of
the medications. When compared to those with graduate education,
respondents without graduate education had significantly more nega-
tive attitudes towards extended-release naltrexone; this finding was not
significant for average attitudes about methadone oral buprenorphine.
Previous formal education or training about MAT in one's capacity
as a court employee was significantly associated with more positive
attitudes towards all medications. Previous MAT education or training
was associated with attitudes towards methadone and oral buprenor-
phine that were a quarter of a point more positive, and attitudes to-
wards extended-release naltrexone that were nearly half a point more
positive.
Roles in the court were explored in the multivariate regression
analyses, and law enforcement officers and prosecutors had sig-
nificantly lower attitudes towards methadone and oral buprenorphine
than did other court personnel (p < 0.05). No significant differences in
attitudes were found towards extended-release naltrexone. See Figure
3.
4. Discussion
The goal of our study was to explore attitudes towards MAT among
criminal justice professionals working in Indiana courts, including
judges, law enforcement officers, probation officers, prosecutors, law
enforcement officers, and healthcare providers. We compared attitudes
across different types of professionals and compared attitudes towards
different types of OUD medications (methadone, oral buprenorphine,
and extended-release naltrexone). We also examined associations be-
tween attitudes and previous formal MAT education or training, as well
as attitudes and demographic variables. Our survey was based on the
survey by Matusow et al. (Matusow et al., 2013) with the addition of
questions about previous formal MAT education or training in the role
of court employee and questions about extended-release naltrexone.
As compared to the nationally representative sample in the
Matusow et al. study, our sample had more respondents; however, our
sample was one of convenience (participants attending an education
summit) and limited to Indiana. Additionally, our respondents were
registered for a statewide educational summit about MAT, so they may
have had more interest in or preexisting knowledge about MAT relative
to respondents in Matusow et al.'s sample and other court personnel in
Indiana. Unlike the Matusow et al. study, our sample included per-
sonnel working in courts other than adult drug courts (e.g. veterans'
courts, family courts, felony courts, misdemeanor courts).
In our sample, some respondents' attitudes were more negative than
those expressed by respondents in the Matusow et al. sample. For ex-
ample, a larger proportion of our sample felt that buprenorphine re-
warded criminals (18% versus 10% in the Matusow et al. study). Also, a
much larger proportion of our sample believed that buprenorphine
prolongs addiction (49% versus 21%) and that methadone prolongs
addiction (59% versus 38%). Interestingly, only 7% of respondents in
our sample believed that extended-release naltrexone rewarded crim-
inals, and only 13% of respondents in our sample believed that ex-
tended-release naltrexone prolongs addiction. Justice personnel may
misperceive methadone and oral buprenorphine as “rewards,” because
the medications are agonists, meaning they activate the opioid re-
ceptors in the brain, even though they do not produce the level of eu-
phoria of the original drug of abuse (Medications to Treat Opioid Use
Disorder, 2018). In contrast, extended-release naltrexone is an antago-
nist, meaning it blocks opioids receptors in the brain and is not asso-
ciated with any level of euphoria. However, the notion that methadone
and buprenorphine “reward” individuals mischaracterizes the role of
agonist medications, which by activating opioid receptors prevent
cravings and withdrawal symptoms despite their potential for misuse.
Even though certain attitudes that respondents in our study ex-
pressed were more negative than those in the Matusow et al. study, our
sample held more positive attitudes towards the three measures found
by Matusow et al. to be predictive of agonist treatment access in adult
drug courts (Matusow et al., 2013). Specifically, our sample had more
Fig. 3. Average Attitudes by Previous Formal MAT Education/Training in Capacity as Court Employee.
*significantly different from each other p < 0.05.
MAT=Medication Assisted Treatment.
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positive attitudes towards the efficacy of methadone and buprenor-
phine in relapse prevention, the efficacy of methadone and buprenor-
phine relative to non-pharmacological approaches, and the importance
of maintaining clients on methadone and buprenorphine. For example,
relative to participants in the Matusow et al. sample, our respondents
were approximately three times as likely to state that methadone and
buprenorphine are more effective than non-pharmacological ap-
proaches to treatment (for methadone, 35% versus 11%; for bupre-
norphine, 41% versus 16%). Likewise, a larger percentage of re-
spondents in our sample believed that clients should be maintained on
methadone (36% versus 31%), and twice as many respondents in our
sample believed that clients should be maintained on buprenorphine
(53% versus 26%). Finally, a larger percentage of respondents in our
sample believed that methadone and buprenorphine prevent relapse
(51% versus 44% for methadone; and 59% versus 45% for buprenor-
phine).
These more positive beliefs in our sample may reflect greater levels
of education about MAT in 2018 relative to 2010 (when the Matusow
et al. study was fielded) and an increase in policy initiatives to expand
MAT, such as a prohibition of SAMHSA funding for drug courts that ban
MAT (Davies, 2015). This interpretation is bolstered by the fact that
previous formal MAT education or training in one's capacity as a court
employee was found to be predictive of positive beliefs towards all
three medications in our study. Alternatively, court personnel in In-
diana (particularly those who attended the educational summit) may
have more positive attitudes towards these three measures relative to
court personnel nationally.
What is particularly striking about our study is the level of positive
attitudes towards extended-release naltrexone as compared to metha-
done and oral buprenorphine. For example, almost three-quarters of our
sample believed that extended-release naltrexone prevented relapse
(71%); more than half believed that extended-release naltrexone should
be used to maintain clients with OUD (62%); and more than half (59%)
believed that extended-release naltrexone is more effective than non-
pharmacological approaches. In fact, even though more evidence exists
for the efficacy of methadone and oral buprenorphine in decreasing
opioid misuse and overdose, our respondents had significantly more
positive beliefs about extended-release naltrexone overall.
More positive attitudes towards extended-release naltrexone may be
explained by historic hostility towards agonist treatments in the crim-
inal justice system (Ludwig & Peters, 2014; Nunn et al., 2009; Sharma
et al., 2016). Such attitudes may be due to the difficulty of finding
trustworthy providers, concerns about misuse or diversion, and lack of
belief in the medications' efficacy (Andraka-Christou, 2017; Matusow
et al., 2013). In contrast, as an antagonist, extended-release naltrexone
has no potential for psychotropic effects, and is therefore less likely to
be diverted than are agonist medications. Additionally, news reports
suggest that the manufacturer of extended-release naltrexone has been
targeting advertisements towards drug courts, particularly judges,
likely due to knowledge of historic hostility towards agonist treatments
in the criminal justice system (Harper, 2017). It is possible that the
manufacturer's marketing activities have been more frequent or intense
in Indiana relative to other states. News reports that Alkermes' mar-
keting efforts disparaged methadone and buprenorphine prompted Se-
nator Kamala Harris to launch an investigation into Alkermes' mar-
keting practices in 2017 (“Senator Harris Launches Investigation into
Pharmaceutical Manufacturer Alkermes Regarding Opioid Addiction
Treatment Manipulation,”, 2017). However, no peer-reviewed study to
date has reviewed the relationship between Alkermes' marketing efforts
and court personnel's attitudes. Court personnel may also feel that an
opioid-free treatment is more appropriate for clients who have already
undergone opioid detoxification (e.g. in jail awaiting trial) as compared
to an agonist treatment. Additionally, since methadone may be pro-
vided only in opioid treatment programs and oral buprenorphine may
be prescribed only by a SAMHSA-waivered provider, respondents may
feel that the logistical barriers to criminal justice participants accessing
those medications are higher than the barriers to accessing extended-
release naltrexone; therefore, respondents may feel that extended-re-
lease naltrexone is a better choice for criminal justice participants. Even
though Matusow et al. did not include questions about extended-release
naltrexone in their study, they did find that logistical barriers (such as
too few providers in an area) influenced adult drug court personnel's
decisions not to allow MAT (Matusow et al., 2013).
More positive attitudes towards naltrexone may also be explained
by distrust of local buprenorphine and methadone providers, because a
previous qualitative study of Indiana problem-solving court judges
found that judges had greater distrust of methadone providers than oral
buprenorphine or extended-release naltrexone providers (Andraka-
Christou, 2017). In that study, judges felt that methadone providers
were either providing overly high dosages or were not properly mon-
itoring participants, both of which amplified judges' fears of methadone
diversion and misuse (Andraka-Christou, 2017).
We are not surprised that law enforcement personnel held more
negative attitudes about oral buprenorphine and methadone relative to
other court personnel. Given their background in criminal justice but
not healthcare, they may view agonist medications through a criminal
justice lens rather than a healthcare lens. In other words, the potential
of agonist diversion and misuse may be more salient to law enforcement
than the well-established treatment efficacy of agonist medications.
In our sample, less than half of respondents (45%) reported having
previously received formal education or training about MAT in the
respondent's capacity as a court employee. Importantly, previous MAT
education/training was significantly associated with positive attitudes
towards all the medications, especially extended-release naltrexone.
These results suggest that initiatives to increase MAT access should
include education for justice personnel working in court settings,
especially since courts are even less likely than other criminal justice
institutions to refer individuals for MAT (Krawczyk et al., 2017). We did
not ask respondents about the method or extent of education received,
so we do not know whether such education was obtained from a
pharmaceutical company, continuing education course, conference, or
independent reading, nor do we know the depth of education provided.
For example, it is possible that the previous formal MAT education or
training was provided by Alkermes, thus explaining the larger effect of
former MAT education or training on attitudes towards extended-re-
lease naltrexone than on attitudes towards oral buprenorphine and
methadone. Future research should examine the most effective format
and provider of MAT education or training for justice personnel.
Our study has several strengths and limitations. We collected in-
formation about a range of medications and were thus able to compare
attitudes about the three most common forms of MAT, including ex-
tended-release naltrexone. By including a wide variety of justice per-
sonnel in our sample, we were able to compare beliefs between dif-
ferent types of personnel working in courts, even though we did not
identify the type of courts in which they work. Additionally, by in-
cluding a question about previous formal MAT education or training in
the respondent's capacity as a court employee, we were able to identify
any potential relationships between MAT education or training and
attitudes, a previously underexplored topic.
Because we surveyed only justice personnel who were registered for
the educational summit, we are limited in our ability to generalize our
results to justice personnel who did not register for the summit.
Furthermore, since participants knew the summit focused on MAT
ahead of time, those participants who completed the survey may be
more likely than others to have a preexisting interest in MAT. If this is
true, then our results may overstate justice personnel's positive attitudes
and understate negative attitudes about MAT relative to attitudes held
by the typical justice personnel in Indiana. Future studies should ex-
plore justice personnel's attitudes towards MAT across the U.S. to detect
any potential differences based on geographic location. Additionally,
future studies should examine differences in attitudes based on the type
of court in which the respondent is employed.
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5. Conclusion
Criminal justice personnel in our study working in court settings
had significantly more negative attitudes towards methadone than oral
buprenorphine, and significantly more negative attitudes towards oral
buprenorphine than extended-release naltrexone. This result may be
explained by historic and current misinformation in the criminal justice
system about agonist treatments. Previous formal MAT education or
training in the respondent's capacity as a court employee was sig-
nificantly associated with positive beliefs about all medications, espe-
cially extended-release naltrexone, suggesting that informational in-
itiatives should target criminal justice professionals in court settings.
Law enforcement officers and prosecutors had significantly more ne-
gative attitudes towards methadone and oral buprenorphine than did
other court personnel, possibly because they view agonist medications
through a criminal justice lens rather than a healthcare lens; in other
words, the potential of agonist diversion and misuse may be more
salient to law enforcement than the well-established treatment efficacy
of agonists. Our results may not be generalizable to other states; ad-
ditionally, it is possible that our respondents had more interest in and
knowledge about MAT relative to other court personnel in the state,
since they were registered for a MAT education summit. Future studies
should further examine the type of MAT education that justice per-
sonnel receive and the most effective format and provider of such
education.
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Appendix A
MEDICATION-ASSISTED TREATMENT INDIANA COURT SURVEY
[Questions marked with an asterisk differ from those in Matusow et al.'s, 2013 survey or did not appear in their survey].
INTRODUCTION
1. What is your profession?*
• Judge
• Probation officers
• Law enforcement officers
• Mental health/SUD counselor-bachelor's degree
• Mental health/SUD counselor-Master's degree or higher
• Defense attorney
• Prosecutor
• Drug Court Services (DCS) Attorney
• Physician (MD)
• Veterans Administration liaison
• Case manager
• Program director/court program coordinator
• Other ________________________
COURT POLICIES
[Only judges received questions about court policies, so they are not reported in this manuscript].
ATTITUDES AND KNOWLEDGE ABOUT MAT
[Matusow et al.'s survey provided three answer choices: disagree, agree, and unsure]













Methadone reduces crime and re-incarceration
Methadone rewards criminals for being drug users
Methadone prolongs addiction
Methadone should be used to maintain clients who have opioid use dis-
order
Methadone is more effective than non-pharmacological approaches to r-
etaining clients in treatment
Methadone interferes with one's ability to drive a car
Methadone reduces or blocks the effect of heroin












Buprenorphine (e.g. Suboxone) reduces relapse
Buprenorphine (e.g. Suboxone) reduces crime and re-incarceration
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Buprenorphine (e.g. Suboxone) rewards criminals for being drug users
Buprenorphine (e.g. Suboxone) prolongs addiction
Buprenorphine (e.g. Suboxone) should be used to maintain clients who have o-
pioid use disorder
Buprenorphine (e.g. Suboxone) is more effective than non-pharmacological ap-
proaches to retaining clients in treatment
Buprenorphine (e.g. Suboxone) interferes with one's ability to drive a car
Buprenorphine (e.g. Suboxone) reduces or blocks the effect of heroin












Extended-release naltrexone (Vivitrol) reduces relapse
Extended-release naltrexone (Vivitrol) reduces crime and re-incarceration
Extended-release naltrexone (Vivitrol) rewards criminals for being drug users
Extended-release naltrexone (Vivitrol) prolongs addiction
Extended-release naltrexone (Vivitrol) should be used to maintain clients who have
opioid use disorder
Extended-release naltrexone (Vivitrol) is more effective than non-pharmacological
approaches to retaining clients in treatment
Extended-release naltrexone (Vivitrol) interferes with one's ability to drive a car
Extended-release naltrexone (Vivitrol) reduces or blocks the effect of heroin
SOURCES OF INFORMATION ABOUT SUBSTANCE USE DISORDER TREATMENTS




6. What is your age?*
• 18–29 years old
• 30–49 years old
• 50–64 years old
• 65 years and over




8. What is the highest level of education you have completed?*
• Some high school





• Some postgraduate work
• Graduate or professional degree
9. Are you or a close family member in recovery from a substance use disorder?*
• Yes
• No
• Prefer not to respond
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